Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Androgen Resistant Prostatic Cancer Clear all
Completed Phase 2 Interventional

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
TroVax, GM-CSF
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 10, 2026, 10:04 AM EDT
Recruiting No phase listed Observational

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07677254
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
17,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

NCT01450683
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease
Interventions
Itraconazole
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Resistance Training and Protein Supplementation for Prostate Cancer Survivors

NCT01909440
View directory record Official record
Conditions
Prostate Cancer
Interventions
exercise intervention, nutritional supplementation, quality-of-life assessment, questionnaire administration, pharmacological study, laboratory biomarker analysis
Behavioral · Dietary Supplement · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
50 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

NCT01540071
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
NRX 194204
Drug
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Early Phase 1 Interventional

Safety and Targeting of Anti-hk2 Antibody in mCRPC

NCT04116164
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Disease
Interventions
111In-DOTA-h11B6
Drug
Lead sponsor
SpectronRX
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

NCT01420861
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of HPN424 in Patients With Advanced Prostate Cancer

NCT03577028
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target, HPN424 2 Prime Step IV 300 ng/kg Target, HPN424 2 Prime Step IV 450 ng/kg Target, HPN424 Fixed SC
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions
enzalutamide, CRLX101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

NCT00110188
View directory record Official record
Conditions
Prostate Cancer
Interventions
ridaforolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

NCT01534052
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

NCT05293496
View directory record Official record
Conditions
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
Interventions
vobramitamab duocarmazine, lorigerlimab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

NCT04677855
View directory record Official record
Conditions
Prostate Cancer
Interventions
PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone
Drug
Lead sponsor
Pellficure Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 10, 2026, 10:04 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

NCT05191017
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms
Interventions
NUV-422, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 10, 2026, 10:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

NCT07258407
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostatic Cancer
Interventions
TD001
Drug
Lead sponsor
T.O.A.D. Oncology SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04631744
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 10, 2026, 10:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastasis
Interventions
Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Early Phase 1 Interventional

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

NCT02113657
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

NCT02047253
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Carfilzomib, Dexamethasone, Acyclovir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 10, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

NCT01174368
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cancer Macrobead placement in abdominal cavity
Biological
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 10, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05241613
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
AC176
Drug
Lead sponsor
Accutar Biotechnology Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 10, 2026, 10:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 10:04 AM EDT